ARTICLE | Clinical News
DMD data to inform Santhera's choice under vamorolone option deal
August 27, 2019 5:37 PM UTC
Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary outcome for clinical efficacy, in a Phase IIa extension study in boys ages 4-7 with Duchenne muscular dystrophy.
Santhera Pharmaceuticals Holding AG (SIX:SANN) holds an option to license the program, which would complement its other pipeline product for DMD, idebenone...